NURECA
|
NURECA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 0.85 | -1.79 | -8.25 | 44.96 | 46.37 |
| CEPS(Rs) | 3.18 | 0.57 | -5.86 | 46.44 | 46.80 |
| DPS(Rs) | - | - | - | 3.00 | 2.00 |
| Book NAV/Share(Rs) | 194.29 | 193.11 | 194.88 | 203.20 | 163.10 |
| Tax Rate(%) | 37.01 | 29.48 | 23.20 | 26.27 | 25.60 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | -6.40 | -10.23 | -12.87 | 20.55 | 27.36 |
| EBIT Margin(%) | 2.10 | -2.06 | -8.83 | 22.85 | 28.42 |
| Pre Tax Margin(%) | 1.10 | -2.54 | -9.21 | 22.57 | 27.71 |
| PAT Margin (%) | 0.69 | -1.79 | -7.08 | 16.64 | 20.62 |
| Cash Profit Margin (%) | 2.61 | 0.57 | -5.03 | 17.19 | 20.80 |
| Performance Ratios | |||||
| ROA(%) | 0.42 | -0.89 | -3.62 | 20.33 | 41.38 |
| ROE(%) | 0.44 | -0.92 | -4.14 | 24.55 | 52.39 |
| ROCE(%) | 1.31 | -1.06 | -5.17 | 33.57 | 67.61 |
| Asset Turnover(x) | 0.60 | 0.49 | 0.51 | 1.22 | 2.01 |
| Sales/Fixed Asset(x) | 9.95 | 9.62 | 10.38 | 34.28 | 89.50 |
| Working Capital/Sales(x) | 0.69 | 0.55 | 0.66 | 1.39 | 1.39 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.10 | 0.10 | 0.10 | 0.03 | 0.01 |
| Receivable days | 7.39 | 10.79 | 11.25 | 2.11 | 10.64 |
| Inventory Days | 105.87 | 119.26 | 152.88 | 67.53 | 43.16 |
| Payable days | 31.48 | 30.60 | 23.46 | 18.53 | 26.74 |
| Valuation Parameters | |||||
| PER(x) | 248.64 | - | - | 30.30 | 12.98 |
| PCE(x) | 66.06 | 449.21 | -51.24 | 29.33 | 12.87 |
| Price/Book(x) | 1.08 | 1.32 | 1.54 | 6.70 | 3.69 |
| Yield(%) | - | - | - | 0.22 | 0.33 |
| EV/Net Sales(x) | 1.52 | 2.29 | 2.06 | 5.00 | 2.23 |
| EV/Core EBITDA(x) | 34.01 | 685.11 | -29.03 | 20.22 | 7.41 |
| EV/EBIT(x) | 65.10 | -102.35 | -22.30 | 20.71 | 7.46 |
| EV/CE(x) | 0.85 | 1.09 | 1.18 | 6.29 | 2.90 |
| M Cap / Sales | 1.92 | 2.78 | 2.70 | 5.33 | 2.82 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 19.29 | -17.42 | -56.44 | 19.72 | 114.69 |
| Core EBITDA Growth(%) | 1,494.46 | 103.88 | -112.51 | -1.79 | 559.74 |
| EBIT Growth(%) | 224.43 | 80.03 | -116.67 | -3.46 | 581.55 |
| PAT Growth(%) | 147.16 | 78.25 | -118.35 | -3.05 | 625.16 |
| EPS Growth(%) | 147.16 | 78.25 | -118.35 | -3.05 | -99.27 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.01 | - | - | - | 0.01 |
| Current Ratio(x) | 15.32 | 20.77 | 21.00 | 5.28 | 7.78 |
| Quick Ratio(x) | 12.10 | 17.44 | 17.12 | 3.89 | 6.24 |
| Interest Cover(x) | 2.11 | -4.20 | -22.87 | 83.30 | 39.89 |
| Total Debt/Mcap(x) | 0.01 | - | - | - | - |
Compare Financial Ratios of peers of NURECA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NURECA | ₹284.0 Cr | 8% | 22% | -8.1% | Stock Analytics | |
| POLY MEDICURE | ₹19,190.4 Cr | -5.3% | 2.1% | -40% | Stock Analytics | |
NURECA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NURECA | 8% |
22% |
-8.1% |
| SENSEX | -1.4% |
1.7% |
4.8% |
You may also like the below Video Courses
